Trial Details
AuthorisedBasic Information
| Clinical ID | c5078 |
|---|---|
| Identifier | EUCTR2018-002629-51-ES |
| Trial Title | A Phase 3b, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Re-induction Therapy With Ustekinumab in Patients With Moderately to Severely Active Crohn Disease - Patient Optimization With ustekinumab Re-induct |
| Trial URL | Visit Original Page |
Study Information
| Study Results | NULL |
|---|---|
| Conditions | Crohn Disease . MedDRA version: 20.0. Level: PT. Classification code 10011401. Term: Crohn's disease. System Organ Class: 10017947 - Gas |
| Interventions | Trade Name: STELARA Product Name: Ustekinumab Product Code: CNTO1275 Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: Ust |
Participant Information
| Sponsor | Janssen-Cilag International N.V. |
|---|---|
| City | NULL |
| Country/Region | France;United States;Spain;Netherlands;Germany;Sweden |
Enrollment Criteria
| Sex Requirement | ALL |
|---|---|
| Age Requirement | NULL |
Study Design
| Study Type | Interventional clinical trial of medicinal product |
|---|---|
| Phase | PHASE3 |
Time Information
| Start Date | NULL |
|---|---|
| Primary Completion Date | NULL |
| Completion Date | NULL |